|Features|| Each single-use disposable assay device, such as the VerifyNow IIb/IIIa or VerifyNow Aspirin Assay, contains all needed reagents to provide analytical results for a specific assay. Assay devices are individually pouched and may be used until the expiration date printed on each kit box and foil pouch.
The assay device consists of the following components:
|Description|| The Company's first commercial product is the VerifyNow System, a point-of-care, bedside instrument with single-use, disposable assay devices . The advantages of the VerifyNow System over previous products are direct use of a vacuum-type blood collection tube (whole blood sample) and a result in minutes. VerifyNow IIb/IIIa, the first assay developed for use on the system is to assess GP IIb/IIIa platelet inhibition in response to abciximab or eptifibatide. VerifyNow Aspirin, the second assay developed for use on the system is to aid in the detection of platelet dysfunction due to aspirin ingestion.
The GP IIb/IIIa inhibitor class of intravenous antiplatelet agents, has demonstrated benefit in treating patients undergoing coronary interventions (e.g. PTCA and stent placement) and acute coronary syndromes. Currently available drugs in this class include ReoPro (Centocor), Integrilin (Millenium Pharmaceuticals) and Aggrastat(Merck & Co.). Accumetrics estimates that over 2.5 million patients annually are candidates for intravenous antiplatelet therapy. Data from clinical trials suggest that both the safety and efficacy of these agents are dependent on achieving a specific level of receptor blockade. Since there are individual variations in the response to these agents, Accumetrics' first product is targeted to address this unmet medical need.
Aspirin, the most commonly used antithrombotic medication in the world, prevents heart attack, stroke, and other vascular events by causing platelet dysfunction, so that platelets will not aggregate. Over 20 million people in the U.S. alone take aspirin daily to prevent platelets from clotting. Clinical data shows that not all patients receive the full benefits of aspirin, therefore it is important to ensure that patients are receiving the expected anti-platelet benefits. Accumetrics second product is designed to address this important medical need.
|Info|| Accumetrics |
Customer Service: (800) 643-1640